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Abstract: There are no data on the outcome of highly active antiretroviral therapy (HAART) in HIV-infected adults in 
rural Burkina Faso. We therefore assessed CD4
+ T-cell counts and HIV-1 plasma viral load (VL), the proportion of naive 
T-cells (co-expressing CCR7 and CD45RA) and
  T-cell activation (expression of CD95 or CD38) in 61 previously 
untreated adult patients from Nouna, Burkina Faso, at baseline and 2 weeks, 1, 3, 6, 9 and 12 months after starting 
therapy. Median CD4
+ T-cell counts increased from 174 (10
th-90
th percentile: 33-314) cells/l at baseline to 300 (114-
505) cells/l after 3 months and 360 (169-562) cells/l after 12 months of HAART. Median VL decreased from 5.8 (4.6-
6.6) log10 copies/ml at baseline to 1.6 (1.6-2.3) log10 copies/ml after 12 months. Early  CD4
+ T-cell recovery was 
accompanied by a reduction of the expression levels of CD95 and CD38 on T-cells. Out of 42 patients with complete 
virological follow-up under HAART, 19 (45%) achieved concordant good immunological (gain of 100 CD4
+ T-cells/l 
above baseline) and virological (undetectable VL) responses after 12 months of treatment (intention-to-treat analysis). 
Neither a decreased expression of the T-cell activation markers CD38 and CD95, nor an increase in the percentage of 
naive T-cells reliably predicted good virological treatment responses in patients with good CD4
+ T-cell reconstitution. 
Repeated measurement of CD4
+ T-cell counts during HAART remains the most important parameter for immunologic 
monitoring. Substitution of repeated VL testing by determination of T-cell activation levels (e.g., CD38 expression on 
CD8
+ T-cells) should be applied with caution. 
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INTRODUCTION 
  In the year 2003, the Ministry of Health in Burkina Faso 
introduced a program for the prevention of mother-to-child 
transmission of the human immunodeficiency virus (HIV) 
using voluntary HIV-counseling and testing and single-dose 
nevirapine in a remote rural area in the north-west of the 
country. The introduction and subsequent extension of that 
service was scientifically evaluated in collaboration between 
the Centre de la Recherche en Santé de Nouna (CRSN) and 
the University of Heidelberg, Germany. This led to 
determination of the HIV prevalence in the region to be 
3.6% and identified HIV-1 circulating recombinant forms 
CRF02_AG and CRF06_cpx as predominant HIV strains [1]. 
Normal values for CD4
+ T-cells in healthy adults in Nouna 
were assessed [2] and a simplified dual platform flow 
cytometric method for determination of lymphocyte subsets 
and T-cell maturation phenotypes was evaluated [3]. In that 
context it was observed that HIV-1-uninfected healthy adult  
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controls living in Nouna had a skewed distribution pattern of 
CD4
+ T-cell maturation phenotypes compared to published 
data from European adults [4]. 
  When highly active antiretroviral therapy (HAART) was 
introduced in Burkina Faso with the help of the Global Fund, 
Nouna was chosen as the first rural site where this treatment 
was made available. We therefore conducted an 
observational cohort study of all patients in Nouna starting 
HAART in 2009 to clarify the following questions: (a) Do 
HIV-1-infected patients with higher baseline proportions of 
naive CD4
+ T-cells and/or lower levels of T-cell activation 
show a more rapid or more extensive recovery of CD4
+ T-
cells under HAART and can these parameters be used as 
predictors of successful immune recovery? (b) Is the 
suppression of viral replication by HAART predicted or 
accompanied by reduced T-cell activation at baseline or 
during therapy and can these parameters be used as 
predictors or indicators of successful virologic treatment 
response? 
MATERIAL AND METHODOLOGY 
  The study was approved by the national ethics committee 
in Ouagadougou, Burkina Faso and the institutional ethics 
committee of the University of Heidelberg, Germany and 
was carried out in compliance with the Helsinki Declaration. Immune Reconstitution During HAART in Burkina Faso  The Open AIDS Journal, 2012, Volume 6    17 
Sixty-one treatment-naïve adult patients were recruited at the 
CRSN from January 2009 and followed until September 
2010. All patients signed an informed consent form prior to 
study entry. Patients were admitted in the study if their CD4
+ 
T-cell counts and/or their clinical status were indicative of 
the necessity to start HAART [5]. Patients were then seen at 
2 weeks and 1, 3, 6, 9 and 12 months after starting HAART. 
Clinical, immunological, and virological assessments were 
done at each time point (only CD4
+ T-cell counting at week 
2 was omitted) using three to five milliliters of K3 -EDTA-
anticoagulated peripheral venous blood collected from each 
patient. Blood samples were transported to the fully 
climatized laboratory facilities at the CRSN. One specimen 
was used for immediate CD4
+ and CD8
+ T-cell counting 
performed on a FACSCount ﬂow cytometer (BD Bioscien-
ces, San Jose, CA). Plasma was obtained from the second 
specimen by short centrifugation at 3000 rpm, frozen at -
40°C and subsequently used for the quantification of viral 
RNA using the m2000rt RealTime HIV-1 test (the m2000rt 
test; Abbott, Chicago, IL) at the Centre Hospitalier Universi-
taire Yalgado Ouedraogo (CHUYO), Ouagadougou, Burkina 
Faso according to manufacturers’ protocols. The third speci-
men was used for multiparametric flow cytometry (FCM) on 
a three-color FACScan ﬂow cytometer (BD Biosciences) 
using the CellQuest-Pro software (version 5.2). The instru-
ment setting was regularly done using CaliBrite beads (BD 
Biosciences). Instrument settings were controlled longitudi-
nally and remained constant during the study. A minimum of 
10,000 events were analysed in the predefined gate for each 
analysis. 
  The distribution of T-cell maturation phenotypes and the 
expression of activation markers was assessed in peripheral 
blood T-cells from HIV-1-infected patients and control 
subjects (n=26) from healthy laboratory and health service 
personnel in Nouna. Monoclonal antibodies (BD Bioscien-
ces) specific for each assay were aliquoted in 3 ml BD FACS 
tubes and 100 μl anticoagulated venous blood were added. 
The percentages of CD4
+ and CD8
+ naïve and memory cell 
subsets were counted after incubating fresh blood with anti-
CD4- or anti-CD8-PerCP, anti-CD45RA-FITC and anti-
CCR7–PE-conjugated monoclonal antibodies. Naive CD4
+ 
or CD8
+ lymphocytes were identified as CD45RA
+CCR7
+ 
cells [3]. T-cell activation was determined with anti-CD95-
PE, anti-CD3-PerCP and anti-CD4-FITC (expression of 
CD95 on CD4
+ and CD4
neg T-cells) and anti-CD38-PE, anti-
CD3-PerCP and anti-CD8-FITC (expression of CD38 on 
CD8
+ and CD8
neg T-cells) essentially as described [6, 7] with 
minor modifications. Both the percentage of marker-positive 
cells (compared to unstained lymphocytes of each patient) 
and the median fluorescence intensity (MFI) obtained from 
FL-2 fluorescence intensity histogram curves of defined 
subpopulations of cells were assessed. CD38 MFI was 
measured on CD38
+ (instead of total) T-cells in order to 
focus our analysis on the CD38
bright CD8
+ T-cell population 
[8]. The two subpopulations of CD95
dim and CD95
bright CD4
+ 
T-cells were separately analyzed since we had previously 
shown that CD95
dim cells essentially correspond to the 
resting/naïve subpopulation of CD4
+ T-cells, whereas 
CD95
bright cells are of an activated/memory phenotype [6]. 
The absolute counts of naive and activated T-cells were 
calculated in HIV-1-infected patients by multiplying the 
percent values obtained on the FACScan ﬂow cytometer 
with absolute CD4
+ and CD8
+ T-cell counts obtained on the 
FACSCount ﬂow cytometer. 
  Unless otherwise indicated, data are given as median 
values and 10
th to 90
th percentiles. For mean differences 
between groups, the 95% confidence interval (CI) is shown. 
Graphical representations (box-and-whisker as well as dot 
plots) were used to describe the development of 
immunological parameters over time. Subjects with an 
increase of at least 100 CD4
+ T-cells/l above baseline after 
12 months of therapy were classified as good immunological 
responders. Patients with a HIV-1 plasma viral load below 
detection limit (< 40 copies/ml) were defined as good 
virological responders [9, 10]. The statistical significance of 
differences between time points as well as between HIV-1-
infected patients and healthy controls or between patient 
groups stratified according to immunological or virological 
response to treatment were analyzed using the non-
parametric Kruskal-Wallis test with Dunn's correction for 
multiple comparisons or the Mann-Whitney U-test. 
Correlations between variables were explored by linear 
regression analysis using Pearson's correlation coefficients 
(r) and the coefficients of determination (R
2) in patients with 
complete data sets at baseline, 6 and 12 month of HAART. 
All calculations were performed using the GraphPad Prism 
software, version 5.00 (Graph Pad Inc., San Diego, 
California, USA). 
RESULTS 
Patients and Treatment 
  A total of 61 patients were recruited for this study. The 
cohort mainly consisted of female individuals (72%) with a 
median age of 35 years (range 30-43 years). CD4
+ T-cell 
counts and HIV-1 plasma viral load levels could be 
determined at baseline in 61 patients (Fig. 1 and Table 1). 
The majority of the patients (n=37; 60%) were in the Center 
for Disease Control (CDC) immunological class C, 23 
patients (38%) were in CDC class B and one patient (2%) in 
CDC class A. Reverse-transcriptase-inhibitor-based HAART 
was started using d4T/3TC/NVP in 43 patients (70%), 
AZT/3TC/EFV in 17 patients (28%) and d4T/3TC/EFV in 
one patient (2%). The numbers of patients seen at each visit 
and of those lost to follow-up are indicated in Fig.  (1). One 
out of 5 patients who died during the observation period of 
our study suffered from severe advanced HIV disease (CD4 
= 07 cells/l); this patient died the very same day of 
inclusion after taking his first dose of HAART. One patient 
suffering from hepatic malignancy died at the end of week 4. 
The other deaths - two patients died at the end of week 4 and 
one patient died after 6 months of HAART - were non-
accidental and apparently associated with HIV infection, but 
the exact causes are not known. Ten plasma samples were 
not suitable for viral load determination. In addition, the 
number of patients with complete multiparameter FCM 
measurements varied at each time point because the 
necessary monoclonal antibodies were not always available 
due to logistic delivery problems in Burkina Faso (Table 1). 
  Seven patients reported a bad drug adherence for several 
days: one patient stopped HAART for 4 days at 2 weeks of 
therapy, two for 7 and 28 days at month 1, three patients 
stopped for 5, 7 and 10 days at month 3, and one patient had 
several treatment interruptions. The unique self-declared 18    The Open AIDS Journal, 2012, Volume 6  Tiba et al. 
reason for bad drug adherence was the occurrence of 
unwanted side effects of therapy such as fatigue, abdominal 
pain, diarrhea and vomiting. In the first month of HAART, 
all patients showed a statistically significant mean increase 
in CD4
+ T-cell counts by 160±97 cells/l (95% CI: 160-214 
cells/l; p<0.0001) and experienced a drop in HIV-1 plasma 
viral load (VL) of more than 2.0 log10 copies per ml. After 
three months of treatment, median VL was significantly 
lower and CD4
+ T-cell counts were significantly higher than 
at baseline before starting HAART (Table 1). 
Immunological Follow-Up 
  This early treatment response was accompanied by a 
significant reduction in the percentage of activated T-cells in 
the peripheral blood (%CD95
+  CD4
+, %CD38
+  CD8
+, and 
%CD38
+ CD8
neg T-cells), while absolute counts of these cells 
increased (Table 1). A more detailed analysis of treatment-
induced changes in T-cell activation and maturation of 
circulating CD4
+  T-cells over time revealed an immediate 
significant reduction in CD38 median fluorescence intensity 
(MFI) and a gradual decrease in CD95 MFI. These changes 
reached statistical significance as compared to baseline 
levels after 6 months of therapy (Fig. 2A-C). The percentage 
of naive CD4
+ T-cells showed a slight but non-significant 
trend towards lower values in the first month of treatment 
(Fig. 2D). In the CD8
+ T-cell compartment, a steep reduction 
in CD38 MFI was seen as early as 2 weeks after starting 
HAART (reaching statistical significance as compared to 
baseline levels after 3 months of therapy). In contrast, the 
gradual decrease in CD95 MFI and the concomitant increase 
in the percentage of naive CD8
+ T-cells reached statistical 
 
Fig. (1). Enrollment and follow-up of HIV-1-infected patients in the study. The number of patients who underwent clinical examination and 
peripheral blood lymphocyte counting is shown for each time point. Immune Reconstitution During HAART in Burkina Faso  The Open AIDS Journal, 2012, Volume 6    19 
significance as compared to baseline only after 6 months of 
therapy (Fig. 3). 
  From month 3 to month 12 of HAART, activation levels 
of CD4
+ and CD8
+ T-cells further consolidated with CD95 
and CD38 MFI showing reduced inter-subject variation. At 
12 months of therapy the MFI-values were significantly 
lower when compared to baseline levels on all T-cell 
subpopulations investigated (Figs. 2A-C,  3A,  B). The 
percentage of naive CD4
+ T-cells returned to pre-treatment 
values (Fig. 2D), while the percentage of naive CD8
+ T-cells 
did not increase beyond the level reached after 6 months of 
therapy (Table 1 and Fig. 3C). There was no correlation 
between CD4
+ T-cells or HIV-1 plasma viral load and the 
extent of activation decay after starting the treatment (data 
not shown). Only the absolute number of naïve T-cells at 12 
months of treatment was significantly correlated with the 
CD4
+ T-cell count at baseline (r=0.591, R
2=0.396, p=0.0003) 
and the CD4
+ T-cell increase at 12 months of therapy 
(r=0.488; R
2=0.238; p=0.002). 
 
  As shown in Table 1, statistically significant differences 
were observed after 12 months of HAART between patients 
and healthy controls for the percentage of naive CD4
+ and 
CD8
+ T-cells (patients < controls), the percentage of CD38
+ 
CD8
neg T-cells and the CD38 MFI on these cells (Fig. 2C) 
and the CD95 MFI on CD4
neg T-cells (Fig. 3A) (patients > 
controls). The expression of CD95 on CD4
+ T-cells and of 
CD38 on CD8
+ T-cells was not significantly different 
between patients at 12 months of therapy and healthy 
controls. Absolute CD4
+ T-cell counts at 12 months of 
HAART were highly correlated with the respective baseline 
values (r=0.754, R
2=0.568; p<0.0001). The absolute increase 
in CD4
+ T-cells after 3 months of HAART however was 
only marginally predictive of CD4
+ T-cell counts at 12 
months of therapy (r=0.367, R
2=0.134; p<0.016). The 
relative increase of CD4
+ T-cells over baseline values was 
highest in those patients who showed the lowest CD4
+ T-cell 
counts before starting treatment (r=-0.631, R
2=0.40; 
p<0.0001). No other association between immuno- 
 
 
 
Fig. (2). Dynamic of CD4
+ T-cell activation and percentage of naive cells. Box plots show the median (horizontal line) and the interquartile 
range, whiskers indicate the 10
th and 90
th percentile. The Y-axis shows the median fluorescence intensity (MFI) in arbitrary units or the 
percentage of naïve CD4
+ T-cells; the X-axis denotes months of therapy, baseline = before starting HAART, CNTRL = healthy adult controls 
from Nouna. The numbers of patients studied at each time point are shown in Table 1.  A: Progressive decrease of the MFI of 
CD95
dimCD4
+CD3
+ cells during treatment. B: Progressive decrease of the MFI of CD95
brightCD4
+CD3
+ cells during treatment. C: 
Progressive decrease of the MFI of CD38
+CD8
-CD3
+ cells at during treatment. D: Dynamic of the frequency of naive CD4
+ T-cells during 
treatment. The Kruskal-Wallis/Dunn's test was used to compare data at different time points; asterisks indicate statistically significant 
differences to baseline values (* = p<0.05, ** = p<0.01, *** = p<0.001). The Mann-Whitney U-test was used to compare HIV-1 infected 
patients at baseline or after 12 months of HAART to healthy controls; comparison bars at the top of the plots indicate the level of statistical 
significance of these differences. 
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Fig. (3). Dynamic of CD8
+ T-cell activation and percentage of 
naive cells. Box plots show the median (horizontal line) and the 
interquartile range, whiskers indicate the 10
th and 90
th percentile. 
The Y-axis shows the median fluorescence intensity (MFI) in 
arbitrary units or the percentage of naïve CD8
+ T-cells; the X-axis 
denotes months of therapy, baseline = before starting HAART, 
CNTRL = healthy adult controls from Nouna. The numbers of 
patients studied at each time point are shown in Table 1.  A: 
Progressive decrease of the MFI of CD95
+CD4
-CD3
+ cells during 
treatment. B: Progressive decrease of the MFI of CD38
+CD8
+CD3
+ 
cells during treatment. C: Dynamic of the frequency of naive CD8
+ 
T-cells during treatment. The Kruskal-Wallis/Dunn's test was used 
to compare data at different time points; asterisks indicate 
statistically significant differences to baseline values (* = p<0.05, 
** = p<0.01, *** = p<0.001). The Mann-Whitney U-test was used 
to compare HIV-1 infected patients at baseline or after 12 months 
of HAART to healthy controls; comparison bars at the top of the 
plots indicate the level of statistical significance of these 
differences. 
virological parameters at baseline or during the first month 
of therapy and the increase in CD4
+ T-cell counts after 12 
months of HAART was seen. 
Immunological and Virological Treatment Response 
after 12 Months of HAART 
  Out of 48 patients with complete immunologic follow-
up, 33 (69%) had a sustained increase in CD4
+ T-cell counts 
of at least 100 cells per l above baseline (classified as good 
immunologic response [IR]). In an intention-to-treat analysis 
(i.e., counting all patients lost to follow-up as treatment 
failure), the rate of good IR was 54% (33 out of 61 patients). 
Before starting HAART, patients with good IR had a slightly 
higher median plasma viral load level than patients without 
good IR; no other statistically significant baseline 
differences between both groups were seen (Supplementary 
Table 1). After 12 months of therapy, patients with good IR 
had significantly higher CD4
+ T-cell counts (together with 
higher absolute counts of CD45RA
+CCR7
+ CD4
+, CD95
+ 
CD4
+, and CD38
+ CD8
neg T-cells) and slightly higher 
absolute numbers of naive CD8
+ lymphocytes (Fig. 4A-D 
and Supplementary Table 2). Out of 42 patients with 
complete immunologic and virologic follow-up at 12 months 
of HAART, 33 (79%) had good IR and 25 (60%) good 
virologic response (VR; defined as a sustained suppression 
of HIV-1 plasma viral load below the detection limit of 40 
RNA-copies per ml). At baseline, patients with good VR had 
a slightly but significantly lower median CD95 MFI on 
CD95
bright CD4
+ T-cells and a lower median CD38 MFI on 
CD8
+ T-cells as compared to virologic non-responders 
(Supplementary Table 1). After 12 months of therapy no 
statistically significant differences between both groups were 
seen - except for the fact that good virologic responders by 
definition had an undetectable HIV-1 viral load 
(Supplementary Table 2). 
Predictors and Indicators of Immunological and 
Virological Treatment Response 
  There was a considerable rate of discordant responses to 
HAART after 12 months of therapy. Only 19 out of 42 
patients (45%) showed good IR and VR, 14 (33%) showed 
good IR but not good VR, 6 (14%) showed good VR but not 
good IR, and 3 patients (7%) had neither good IR nor VR 
(Supplementary Table 3). At baseline, patients with a 
discordant treatment response (good IR but not good VR) - 
when compared to patients with a concordant good response 
- had significantly higher CD38 MFI values on circulating T-
cells [arbitrary units; median (10
th to 90
th percentile): 509 
(154-886)  vs 217 (123-1125) on CD38
+ CD8
+  T-cells, 
p<0.01; 482 (221-738) vs 292 (192-749) on CD38
+ CD8
neg 
T-cells, p<0.001]. Also the percentage of CD95
+CD4
+ T-
cells was slightly but significantly higher [99 (93-100)% vs 
97 (83-99)%, p<0.01] (Supplementary Table 3). After 12 
months of HAART, only the percentage of naive CD8
+ T-
cells indicated a statistically significant difference between 
these two groups, being nearly twice as high in patients with 
concordant good response to therapy [16 (2-28)%] as 
compared to patients with discordant treatment response [8 
(2-17)%, p<0.01] (Supplementary Table 3). A lack of IR 
after 12 months of HAART was present in 6 out of 25 
patients with good VR. Despite significantly lower CD4
+  
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Table 1.  Comparison of HAART-Induced Changes on Immunological and Virological Prameters in HIV-1 Patients at Baseline 
and After 3, 6, 9 and 12 Months of Therapy and HIV-1 Negative Healthy Adult Control Subjects from Nouna. Median 
Values are Shown with the 10th - 90th Percentile in Parentheses. ND= Not Determined, NA= Not Applicable 
 
Parameter  At Baseline 
(A) 
At 3 Months 
(B) 
At 6 Months 
(C ) 
At 9 Months 
(D) 
at 12 Months 
(E) 
CNTRL 
(F) 
Kruskal-Wallis Statistic  
with Dunn's Multiple  
Comparison Test 
CD4
+ T-cells               
n  =  61 56 55 51 48  26  ND 
CD4
+ T-cell count (cells/l)  174 (33-314)  300 (114-505)  353 (128-500)  330 (150-541)  360 (169-562)  ND  A<B=C=D=E;  
p<0.0001 
naive CD4
+ T-cells               
n  =  50 42 38 22 36  26  ND 
CD45RA
+ CCR7
+ (% of CD4
+ T-cells)  16 (3-36)  12 (2-37)  13 (4-33)  15 (3-33)  17 (5-37)  26 (16-43)  A=B=C=D=E<F;  
p<0.0001 
CD45RA
+ CCR7
+ CD4
+ T-cell count  
(cells/l)  23 (2-77)  20 (4-143)  40 (8-134)  56 (6-125)  67 (8-163)  ND  A=B=C=D=E;  
p>0.05 
activated CD4
+ T-cells               
n=  53 49 41 45 36  26  ND 
CD95
+ (% of CD4
+ T-cells)  97 (85-100)  95 (89-99)  95 (89-99)  87 (73-98)  88 (72-98)  91 (77-98)  A=B=C>D=E=F;  
p<0.0001 
CD95
+ CD4
+ T-cells (cells/l)  173 (37-304)  281 (109-434)  281 (73-522)  247 (91-453)  298 (118-504)  ND  A<B=C=D=E;  
p<0.0001 
CD38
+ (% of CD8
neg T-cells)  91 (81-96)  83 (71-92)  78 (73-93)  75 (66-84)  76 (67-86)  59 (34-96)  A>B=C=D=E>F;  
p<0.0001 
CD38
+ CD8
neg T-cells (cells/l)  156 (12 -273)  223 (97-439)  258 (68-405)  259 (109-429)  292 (95-436)  ND  A<B=C=D=E;  
p<0.0001 
CD8
+ T-cells               
n  =  61 56 55 47 43  26  ND 
CD8
+ T-cell count (cells/l) 835  (385-2000)  931 (405-1695)  957 (385-1684)  816 (348-1820)  905 (423-2000)  ND  A=B=C=D=E;  
p>0.05 
naive CD8
+ T-cells               
n=  61 56 55 51 48  26  ND 
CD45RA
+ CCR7
+ (% of CD8
+ T-cells)  4 (1-9)  8 (2-25)  8 (3-20)  10 (4-24)  11 (3-18)  27 (6-37)  A<B=C=D=E<F;  
p=0.0002 
CD45RA
+ CCR7
+ CD8
+ T-cell count  
(cells/l)  19 (2-111)  66 (16-198)  72 (18-183)  72 (20-199)  90 (22-234)  ND  A<B=C=D=E;  
p=0.002 
activated CD8
+ T-cells               
n=  53 49 41 45 36  26  ND 
CD95
+ (% of CD4
neg T-cells)  97 (91-100)  95 (88-99)  95 (89-99)  87 (65-95)  89 (72- 97)  64 (21-81)  A=B=C>D=E=F;  
p<0.0001 
CD95
+ CD4
neg T-cells (cells/l) 794  (470  -1959)  819 (444-1633)  883 (422-1420)  608 (339-1591)  785 (340-1773)  ND A=B=C=D=E;  p>0.05 
CD38
+ (% of CD8
+ T-cells)  98 (90-99)  92 (81-99)  88 (71-94)  85 (68-95)  85 (63-95)  83 (63-98)  A>B=C=D=E=F;  
p<0.0001 
CD38
+ CD8
+ T-cells (cells/l) 871  (481-1803)  843 (429-1447)  825 (320-1287)  773 (326-1834)  695 (396-1783)  ND  A=B=C=D=E;  
p>0.05 
HIV-1 plasma viral load               
n  =  61 51 45 45 42  ND  ND 
log10 copies per ml  5.8 (4.6-6.6)  2.1 (1.6-2.8)  1.6 (1.6-2.4)  1.6 (1.6-2.1)  1.6 (1.6-2.3)  NA  A>B=C=D=E; p<0.0001 22    The Open AIDS Journal, 2012, Volume 6  Tiba et al. 
T-cell counts no differences were seen in the expression of 
T-cell activation markers or in the percentage of naive T-
cells when compared to patients with concordant good IR 
and VR. We also examined the predictive value of several 
indicators of T-cell activation and maturation at baseline and 
during treatment. Despite significant differences between 
virologic responders and non-responders and despite 
significant correlations of these markers with plasma VL 
levels at baseline (data not shown), the expression patterns of 
CD95 or of CD38 on T-cell subsets in the peripheral blood 
could not reliably indicate or predict the presence or absence 
of effective suppression of viral replication (see 
Supplementary Fig. 1). 
DISCUSSION 
  In our study we show that even under the environmental 
conditions in rural Burkina Faso CD4
+ T-cell reconstitution 
following HAART is a biphasic phenomenon. It is 
characterized by a first phase mainly constituted of memory 
cells and a second phase during which naive T-cells 
progressively appear in the peripheral blood [11, 12]. CD4
+ 
T-cell reconstitution after 12 months of therapy was similar 
to the observations from the CIPRA-SA cohort in South 
Africa, for which an increase from a mean (± standard error 
of the mean) of 186±8 cells/l at baseline to 334±18 cells/l 
at month 12 was reported [13]. The absolute rise in CD4
+ T-
cell counts after 12 months of HAART was mainly 
determined by the baseline CD4
+  T-cell counts in our 
patients. More immunological benefit can be expected when 
therapy is started at higher CD4
+ T-cell counts than actually 
practiced in Nouna [14]. Interestingly, not a single patient 
showed signs or symptoms of HAART-induced immune 
reconstitution inflammatory syndrome, a potential severe 
side-effect of successful T-cell regeneration in patients with 
advanced HIV-disease [15]. 
  Over the entire year of treatment, a slight but continuous 
increase in the percentage of naive CD8
+ T-cells was seen 
 
Fig. (4). Difference of the level of immune reconstitution between groups of patients according to immunologic or virologic response at 12 
months of HAART. Dot plots show results obtained in individual patients, the group median is indicatd by a horizontal line. The Y-axis 
shows the number of cells in the specific CD4
+ subpopulation. The X-axis denotes patient groups stratified according to immunological or 
virological response to treatement (IR=immunologic responders; NIR= immunologic non-responders; VR= Virologic responders; NVR= 
virologic non-responders. A: Comparison of CD4
+ T-cell counts between patient groups. B: Comparison of naïve CD4
+ T-cell counts 
between patient groups. C: Comparison of CD95
+CD4
+ T-cell counts between patient groups. D: Comparison of CD38
+CD8
- T-cell counts 
between patient groups. The Mann-Whitney U-test was used to compare groups; comparison bars at the top of the plots indicate the level of 
statistical significance of these differences. Immune Reconstitution During HAART in Burkina Faso  The Open AIDS Journal, 2012, Volume 6    23 
until month 6 of therapy. At the same time, the percentage of 
naive CD4
+ T-cells reached pre-treatment levels again, and 
expression of the CD95 receptor was significantly reduced as 
compared to baseline. Regeneration of both naive CD4
+ and 
CD8
+  T-cells indicates that repetitive exposure to tropical 
infectious and non-infectious agents does not disturb the 
process of T-cell reconstitution under HAART in West 
African patients. After 12 months of HAART, however, 
HIV-1-infected patients in Nouna still had a significantly 
lower percentage of circulating naive CD8
+ T-cells than 
healthy adult controls. A comparison with the reference 
values for naive T-cells in our study area [3] revealed lower 
absolute numbers of naive CD4
+ T-cells after 12 months of 
HAART than in healthy controls (mean±standard deviation: 
228±146 cells per l; 5
th to 95
th percentile: 35 to 496 cells 
per l). Absolute numbers of naive CD8
+ T-cells after 12 
months of HAART were also below the values observed in 
healthy adults (mean±standard deviation: 173±103 cells per 
l; 5
th to 95
th percentile: 36 to 363 cells per l). 
  Early immunologic treatment response was accompanied 
by a significant reduction in the percentage of activated T-
cells in the peripheral blood, while absolute counts of these 
cells increased. A similar rapid decrease in the activation 
levels of peripheral blood T-cells has been described in 
European cohorts [18-20] and in studies on HIV-1-infected 
Africans receiving antiretroviral therapy [7, 13, 21]. This 
decrease may thus be explained by a causal association 
between high levels of HIV-1 replication leading to T-cell 
activation, followed by an acceleration in the proliferation 
rate of naive T-cells. The slow increase in naive T-cells 
during HAART may depend on thymopoiesis and on 
homeostatic autoproliferation of postthymic T-cells in the 
periphery when filling empty spaces in a lymphopenic host. 
Without additional measurements (e.g., quantification of the 
fraction of Ki-67
+ proliferating naive T-cells or of T-cell 
receptor rearrangement excision cycles) it is not possible to 
discern the relative contribution of these regeneration 
pathways [16]. According to Di Mascio et al. [17], HAART-
induced changes in naive T-cell dynamics cannot be 
explained by changes in thymic output but rather depend on 
a treatment-induced reduction in proliferation rates of naive 
T-cells. These cells may be lost at a lower rate into the 
activated/memory compartment once the HIV-1-induced 
chronic hyperactivation is reduced by effective HAART. 
Naive T-cells may then participate in homeostatic 
autoproliferation leading to the late increase in resting naive 
T-cells observed in the Nouna patient cohort. 
  Analysis of the development of expression patterns of 
CD95 on peripheral blood T-cells supports this 
interpretation. We [6, 22] and others [23] had shown in the 
past that the cell populations constituting the CD95
dim and 
the CD95
bright peak of CD4
+ T-cells correspond to resting 
naïve and activated memory cells, respectively. In HIV-
infected individuals, the slow and continuous change in the 
density of CD95 receptors on these cells seems to be more 
closely connected to the slow increase in the percentage of 
CD45RA
+CCR7
+ cells than to the rapid decrease in 
expression of the CD38 receptor. After 12 months of 
HAART, however, HIV-1-infected patients in Nouna still 
had a slightly higher expression of CD95 on CD4
neg (i.e., 
CD8
+) T-cells than healthy adult controls. The percentage of 
naive CD8
+ T-cells was reduced in HIV-1-infected patients, 
and the expression of CD38 on CD8
+ T-cells was not 
significantly different from the controls. Skewed maturation 
and increased activation of peripheral blood T-cells in HIV-
1-infected patients after 12 months of HAART compared to 
healthy controls may therefore be explained by several 
factors: (1) Previous HIV-induced T-cell loss may not be 
fully compensated by thymic reconstitution and 
autoproliferation of naive T-cells after 12 months of 
HAART. This may lead to homeostatic expansion of these 
cells in the periphery causing increased expression of CD95 
or CD38 on circulating naive T-cells as a sign of cellular 
cycling. (2) In response to environmental stimuli circulating 
naive T-cells may become constitutively activated. We had 
observed high prevalences of, e.g., CMV and HBV in the 
study area [24]. T-cell responses to viral infection would be 
expected to increase CD38 expression in the CD8
+ T-cell 
compartment [25]. However, after 12 months of HAART, 
HIV-1-infected patients in Nouna showed a similar 
expression of CD38 on CD8
+ T-cells as healthy controls. 
Differences in the exposure to other viral infections than 
HIV is thus an unlikely cause of the deviations observed in 
the CD4
+ and CD8
+ T-cell compartments in these 
individuals. (3) The residual viral replication - which was 
seen in 17 patients without good virological response (NVR) 
- may also act as a continuous T-cell stimulus. However, 
continuing HIV-replication would also be expected to 
increase primarily the expression of CD38 on CD8
+ T-cells 
[7]. 
  These results point to a common problem in flow 
cytometric analysis of T-cell activation markers in HIV-
infected individuals. In the individual patient with rising 
CD4
+  T-cell counts under HAART, an increase in CD38 
expression on CD8
+ T-cells most probably indicates a rise in 
viral load (see supplementary material). In the lymphopenic 
patient with advanced disease and continuously low CD4
+ T-
cell counts (<50 cells l
-1) despite HAART, the effects of 
cell cycling due to homeostatic autoproliferation may be the 
main determinants of the expression levels of molecular 
markers of T-cell activation. It is therefore not surprising that 
we were not able to predict a good virological treatment 
response by measuring T-cell activation - despite the 
statistically significant correlations between these 
parameters. While the predictive value of CD38 expression 
on CD8
+ peripheral blood T-cells for virological treatment 
failure has been demonstrated in patient cohorts in South 
Africa [13] and Thailand [26], findings similar to ours were 
reported by Ondoa and colleagues in patients from Abidjan, 
Côte d'Ivoire [7]. Despite appearing to be a sensitive detector 
of HIV-1 plasma viral load, the percentage of CD38
+ CD8
+ 
T-cells lacks specificity if used as a screening test for the 
sensitive detection of early virological failure. Even the use 
of CD38 median fluorescence intensity did not improve the 
capacity of the test to discriminate treatment success and 
treatment failure (see also Supplementary Fig. 1). 
Assessment of CD38 expression on CD8
+ T-cells may be 
more relevant if it were restricted to the memory (CD45RO
+) 
subpopulation of CD8
+ T cells [27] or if the percentage of 
CD8
+ CD38
bright T cells (defined as having >8,500 CD38 
binding sites per cell) were measured [8]. However, the 
observation that assessment of longitudinal changes of these 
parameters in the individual patient under HAART may 
indicate changes of plasma viral load levels [13] is 24    The Open AIDS Journal, 2012, Volume 6  Tiba et al. 
corroborated by similar observations in single patients of our 
West African patient cohort (see Supplementary Table 4). 
Table 2.  Putting Research Findings on the Dynamics of Naive 
T-Cells Coexpressing CD45RA and CCR7 and the 
T-Cell Activation Markers CD95 and CD38 in HIV-
1-Infected Africans During the First Year of Highly 
Active Antiretroviral Therapy (HAART) into the 
Context of Previously Published Evidence 
 
What is Already Known on this Topic: 
•  CD4
+  T-cell reconstitution following HAART is a biphasic 
phenomenon characterized by an early increase of memory cells and 
a late phase when naïve  T-cells progressively appear in the 
peripheral blood [11, 12, 13]. However, none of these studies used 
CD45RA and CCR7 as markers of naïve T-cells in HIV-infected 
Africans. 
•  Expression levels of CD38 on peripheral blood T-cells rapidly 
decrease in HIV-1-infected individuals receiving antiretroviral 
therapy both in Europe and in Africa [7, 13, 18, 20, 21]. 
•  The activation marker CD95 is differentially expressed on CD4
+ T-
cells with a resting naïve or activated memory phenotypes, 
respectively [6, 22, 23]. These expression patterns have not been 
studied in HIV-1-infected Africans and only rarely in Europeans [6, 
19]. 
•  The validity of CD38 expression on CD8
+ peripheral blood T-cells 
as a predictor of virological treatment failure in HIV-1-infected 
individuals receiving antiretroviral therapy is controversial [7, 13, 
26]. 
What this Study Adds: 
•  Early immunologic and virologic treatment response in HIV-1-
infected patients receiving HAART was accompanied by a 
significant reduction in the percentage of activated T-cells in the 
peripheral blood as well as an immediate significant reduction in 
CD38 median fluorescence intensity (MFI), while CD95 MFI 
decreased only gradually. 
•  The slow and continuous change in the density of CD95 receptors 
on  CD95
dim and CD95
bright CD4
+ T-cells (which correspond to 
resting naïve and activated memory cells, respectively) reflects 
more closely the slow increase in the percentage of 
CD45RA
+CCR7
+  naïve T-cells than the rapid decrease in CD38 
MFI during HAART. 
•  Despite significant correlations of these markers with HIV-1 plasma 
viral load levels at baseline, neither the expression pattern of CD95 
nor of CD38 on T-cell subsets in the peripheral blood reliably 
indicates or predicts the presence or absence of effective 
suppression of viral replication during HAART. 
 
CONCLUSION 
  Repeated assessment of CD4
+ T-cell counts remains the 
most important measure of immunological follow-up of 
HIV-infected patients before and during HAART. The 
expression of the T-cell activation markers CD95 and CD38 
may be an indicator of the overall immune recovery in 
patients with advanced disease receiving HAART. T-cell 
activation markers should be used with caution as a 
substitute for repetitive measurements of HIV-1 plasma viral 
load in order to assess the virologic response to treatment. 
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SUPPLEMENTARY MATERIAL 
 Supplementary  Fig.  (1). Receiver operating 
characteristics (ROC) curves of median fluorescence 
intensity of activation markers on peripheral blood T-cells 
show the lack of usefulness of these parameters as indicators 
of poor virologic treatment reponse at 12 months of 
HAART. ROC curves were generated using the MS Excel 
template of Marley W. Watkins available at 
http://www.public.asu.edu/~mwwatkin/Software/ROCanalys
is.xls. Abbreviation: AUC = area under the ROC curve. 
 Supplementary  Table  1. Immunological and virological 
parameters in HIV-1 infected subjects at baseline, i.e., before 
starting HAART. Median values are shown with their 10
th - 
90
th centile in parentheses. Patients with complete 
immunological follow-up (n=48) were grouped according to 
response to treatment: IR = good immunologic response, 
NIR = immunologic non-response. Patients with complete 
virologic follow-up (n=42) were divided into the following 
groups: VR = good virologic response, NVR = virologic 
non-response. The Mann-Whitney U-test was used to 
compare the IR vs NIR and VR vs NVR groups, respectively. 
 Supplementary  Table  2. Immunological and virological 
parameters in HIV-1 infected subjects after 12 months of 
HAART. Median values are shown with their 10
th - 90
th 
centile in parentheses. Patients with complete immunological 
follow-up (n=48) were grouped according to response to 
treatment: IR = good immunologic response, NIR = 
immunologic non-response. Patients with complete virologic 
follow-up (n=42) were divided into the following groups: 
VR = good virologic response, NVR = virologic non-
response. The Mann-Whitney U-test was used to compare 
the IR vs NIR and VR vs NVR groups, respectively. 
 Supplementary  Table  3. Immunological and virological 
parameters in HIV-1 infected subjects at baseline and after 
12 months of HAART. Median values are shown with their 
10th - 90th centile in parentheses. Patients (n=42) are 
grouped  according to response to treatment (IR = good 
immunologic response, VR = good virologic response, NIR 
= immunologic non-response, NVR = virologic non-
response); the Mann-Whitney U-test was used to compare 
the IR and VR vs IR but NVR group. 
 Supplementary  Table 4. Analysis of individual treatment 
responses to HAART in patients with virological treatment 
failure during 12 months of HAART. Longitudinal data from 
5 patients with CD4 counts ranging from 7 to 231 cells l
-1 
at baseline are shown. Abbreviations: M= months of 
treatment; MFI = median fluorescence intensity; ND = not 
determined; VL= viral load (log10 copies/ml). 
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